Oric Pharmaceuticals, Inc. financial data

Symbol
ORIC on Nasdaq
Location
240 E. Grand Ave., 2 Nd Floor, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.28K % -11%
Debt-to-equity 9.91 % +5.54%
Return On Equity -51.8 % -28.8%
Return On Assets -47.1 % -28.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97.1M shares +37.7%
Common Stock, Shares, Outstanding 86.2M shares +27.4%
Entity Public Float 471M USD +13.6%
Common Stock, Value, Issued 9K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 78.1M shares +11.1%
Weighted Average Number of Shares Outstanding, Diluted 78.1M shares +11.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 31.3M USD +14.5%
Operating Income (Loss) -150M USD -19.6%
Nonoperating Income (Expense) 12.4M USD -13.4%
Net Income (Loss) Attributable to Parent -137M USD -23.9%
Earnings Per Share, Basic -1 USD/shares -8.57%
Earnings Per Share, Diluted -1 USD/shares -8.57%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75.9M USD +52.2%
Assets, Current 291M USD -1.18%
Property, Plant and Equipment, Net 2.76M USD -4.03%
Operating Lease, Right-of-Use Asset 8.38M USD -8.36%
Other Assets, Noncurrent 7.76M USD -16.6%
Assets 347M USD +5.46%
Accounts Payable, Current 3.13M USD +35.6%
Accrued Liabilities, Current 14.9M USD -13.4%
Liabilities, Current 18.1M USD -7.62%
Operating Lease, Liability, Noncurrent 6.17M USD -17.3%
Other Liabilities, Noncurrent 4.81M USD -30.9%
Liabilities 22.9M USD -13.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 187K USD
Retained Earnings (Accumulated Deficit) -629M USD -27.9%
Stockholders' Equity Attributable to Parent 324M USD +7.14%
Liabilities and Equity 347M USD +5.46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.5M USD -7.78%
Net Cash Provided by (Used in) Financing Activities 125M USD
Net Cash Provided by (Used in) Investing Activities 22.5M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 86.2M shares +27.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.1M USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.4M USD +51.7%
Deferred Tax Assets, Valuation Allowance 173M USD +29.8%
Deferred Tax Assets, Gross 175M USD +29.1%
Operating Lease, Liability 9.36M USD -8.38%
Depreciation 302K USD +15.7%
Payments to Acquire Property, Plant, and Equipment 387K USD +77.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -137M USD -23.8%
Lessee, Operating Lease, Liability, to be Paid 10.6M USD -12%
Property, Plant and Equipment, Gross 10.8M USD +9.57%
Operating Lease, Liability, Current 3.27M USD +18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.46M USD +29.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.3M USD +15.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.22M USD -32.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.77M USD +3.51%
Deferred Tax Assets, Operating Loss Carryforwards 90.7M USD +19.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 3.74M USD +32.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.05M USD -62.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.59M USD -3.43%
Share-based Payment Arrangement, Expense 23.4M USD +31.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%